CN1239156C - 一种防止或治疗钙质缺损的口服溶液及其制备方法 - Google Patents
一种防止或治疗钙质缺损的口服溶液及其制备方法 Download PDFInfo
- Publication number
- CN1239156C CN1239156C CN 03104587 CN03104587A CN1239156C CN 1239156 C CN1239156 C CN 1239156C CN 03104587 CN03104587 CN 03104587 CN 03104587 A CN03104587 A CN 03104587A CN 1239156 C CN1239156 C CN 1239156C
- Authority
- CN
- China
- Prior art keywords
- calcium
- preparation
- oral administration
- gluconate
- administration solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 6
- 229940100688 oral solution Drugs 0.000 title abstract 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960005069 calcium Drugs 0.000 claims abstract description 26
- 239000011575 calcium Substances 0.000 claims abstract description 26
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 16
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 11
- 229960005337 lysine hydrochloride Drugs 0.000 claims abstract description 11
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 10
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 10
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 10
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 10
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 10
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 10
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 8
- 239000001527 calcium lactate Substances 0.000 claims abstract description 8
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 8
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 230000001954 sterilising effect Effects 0.000 claims abstract 2
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract 2
- 206010006956 Calcium deficiency Diseases 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 208000007442 rickets Diseases 0.000 abstract description 8
- 208000001132 Osteoporosis Diseases 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 8
- IHBCFWWEZXPPLG-UHFFFAOYSA-N [Ca].[Zn] Chemical compound [Ca].[Zn] IHBCFWWEZXPPLG-UHFFFAOYSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010048259 Zinc deficiency Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 102000014823 calbindin Human genes 0.000 description 3
- 108060001061 calbindin Proteins 0.000 description 3
- 230000037315 hyperhidrosis Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03104587 CN1239156C (zh) | 2003-02-19 | 2003-02-19 | 一种防止或治疗钙质缺损的口服溶液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03104587 CN1239156C (zh) | 2003-02-19 | 2003-02-19 | 一种防止或治疗钙质缺损的口服溶液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1432359A CN1432359A (zh) | 2003-07-30 |
CN1239156C true CN1239156C (zh) | 2006-02-01 |
Family
ID=27634013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03104587 Expired - Lifetime CN1239156C (zh) | 2003-02-19 | 2003-02-19 | 一种防止或治疗钙质缺损的口服溶液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1239156C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103417489A (zh) * | 2012-05-16 | 2013-12-04 | 黄华 | 一种葡萄糖酸钙锌颗粒剂的制法 |
CN103462947B (zh) * | 2013-09-22 | 2015-09-16 | 贵州联盛药业有限公司 | 葡萄糖酸钙锌颗粒剂及其制法 |
CN105412061A (zh) * | 2015-12-04 | 2016-03-23 | 浙江浙北药业有限公司 | 一种葡萄糖酸钙锌口服溶液的制备方法 |
-
2003
- 2003-02-19 CN CN 03104587 patent/CN1239156C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1432359A (zh) | 2003-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1085084A (zh) | 治疗和预防应激性肠综合症的方法及其所用的药物组合物 | |
CN101073580A (zh) | 复合维生素注射液及其制备方法 | |
JPH04502758A (ja) | 経口投与のためのn―アセチルグルコサミン製剤 | |
CN107417556A (zh) | L‑天门冬氨酸螯合钙及其制备方法 | |
WO2006133055A2 (en) | Method and composition for increasing the alkalinity of the body | |
CN1239156C (zh) | 一种防止或治疗钙质缺损的口服溶液及其制备方法 | |
CN1074762C (zh) | L-苏糖酸铬盐、其制备方法及其应用 | |
CN1060336C (zh) | 一种防治钙质缺损的药物及其制备方法 | |
CN1615906A (zh) | 十八复方氨基酸注射液及其制备方法 | |
CN1850112A (zh) | 聚乙二醇-电解质口服溶液 | |
CN1245179C (zh) | 血源素补血剂 | |
CN1301109C (zh) | 钙锌铁口服液及其制备方法 | |
CN101607080B (zh) | 治疗糖尿病的口服药物及其制备方法 | |
CN1027959C (zh) | 锌钙口服液及其配制方法 | |
CN113368039A (zh) | 一种有机钙口服液及制备方法 | |
CN1736402A (zh) | 速效牙痛水 | |
CN101804068B (zh) | 聚乙二醇-电解质口服溶液 | |
CN1748771A (zh) | 一种治疗糖尿病的中药药物组合物及其制备方法和应用 | |
CN100364527C (zh) | 一种维生素c与精氨酸的组合物及其应用 | |
CN1120725C (zh) | 治疗骨质疏松、增生的药物及其制备方法 | |
CN1242766C (zh) | 一种预防和治疗慢性疲劳综合症的药物及其制备方法 | |
CN1061256C (zh) | 外涂降压膏 | |
CN1317007C (zh) | 一种珍珠解毒口服液及制备方法 | |
CN101439109A (zh) | 一种治疗肠胃病的中草药组合物及其制备方法和用途 | |
WO2008028547A1 (en) | Liquid composition for prevention and/or treatment of different bone metabolic diseases, uses thereof, and preparation process therefore |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: HUBEI WUSHI PHARMACEUTICAL Co.,Ltd. Document name: Notice of amendment to the petition for invalidation (1) |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: HUBEI WUSHI PHARMACEUTICAL Co.,Ltd. Document name: The request for invalidation is deemed not to be presented |
|
C56 | Change in the name or address of the patentee |
Owner name: AONUO ( CHINA ) PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: AONUO PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Baoding City, Hebei province 071051 woodland Street No. 1099 Patentee after: AONUO (CHINA) PHARMACEUTICALS Co.,Ltd. Address before: Baoding City, Hebei province 071051 woodland Street No. 1099 Patentee before: AONUO PHARMACEUTICAL Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: BEIJING MEDCONXIN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Assignor: AONUO (CHINA) PHARMACEUTICALS Co.,Ltd. Contract fulfillment period: 2009.9.15 to 2014.9.14 Contract record no.: 2009110000215 Denomination of invention: Oral Solution for preventing and treating acalcerosis and its prepn process Granted publication date: 20060201 License type: Exclusive license Record date: 20090928 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.15 TO 2014.9.14; CHANGE OF CONTRACT Name of requester: BEIJING MEIDI KANGXIN PHARMACEUTICAL TECHNOLOGY CO Effective date: 20090928 |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060201 |